StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

Research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued to investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Up 2.7 %

AKTX stock opened at $1.52 on Friday. Akari Therapeutics has a 52-week low of $1.08 and a 52-week high of $5.50. The business has a 50-day simple moving average of $1.56 and a two-hundred day simple moving average of $2.40.

Institutional Investors Weigh In On Akari Therapeutics

An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC lifted its position in shares of Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after purchasing an additional 28,511 shares during the period. Omnia Family Wealth LLC owned 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent quarter. 5.06% of the stock is owned by hedge funds and other institutional investors.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.